The Preclinical And Clinical Effects Of Cannabis And Cannabinoids On Cardiovascular Health

The Preclinical and Clinical Effects of Cannabis and Cannabinoids on Cardiovascular Health is a comprehensive investigation into the cardiovascular health effects of marijuana use. As the prevalence of cannabis use increases both recreationally and clinically, a shroud of misinformation exists in academia, the public, and clinical realms. Further, since different studies show contradictory results it is hard to determine the exact benefits for cannabis use. This book will focus on a specific set of cardiovascular diseases plaguing the current population and the effects of cannabis will be addressed from numerous viewpoints including human physiological and clinical disease outcomes to issues in public health. By gathering this information in a way that addresses numerous viewpoints the book serves as a comprehensive reference and clinical guide Compiles the numerous contradictory reports about the effects of marijuana and cardiovascular disease for ease in comparison Examines the mechanisms that have shown how marijuana use might contribute to the development of chronic cardiovascular conditions and/or acutely trigger cardiovascular events Includes coverage of the drug's role in pharmacotherapy

Medicinal Usage of Cannabis and Cannabinoids offers readers a comprehensive reference on the medical usage and symptom relief provided by these compounds in a variety of disorders. With coverage of neurological diseases like Alzheimer’s and Parkinson’s, and a wide range of other afflictions including depression, anxiety, nausea and cancer, this broad coverage allows readers to learn about symptom control, along with the physiological, psychological and pharmacological effects of these compounds. Unique case reports are provided as well. This volume provides a platform for research on the use of these compounds in improving patient care, brain function and neurological dysfunction. Summarizes the medicinal usage of cannabis and cannabinoids in a variety of conditions Contains chapter abstracts, key facts, a dictionary and a summary Examines symptom control of conditions such as depression, anxiety and sleep Discusses cannabis usage in Alzheimer’s, Parkinson’s, Multiple Sclerosis and cancer Features case reports and chapters on the physiological, psychological and pharmacological effects

This book provides a comprehensive overview of current knowledge of cannabinoid activity in human physiology and points out the importance of endocannabinoid system for the maintenance of human health and treatment of diseases. Each chapter has been organized with the aim to cover basic concepts in the modulation of endocannabinoid system in both physiological and pathological conditions, thanks to the integration of data from experimental animal models and clinical observations. A special focus has been put on the medical use of cannabinoids and on the targeting of endocannabinoid system as new therapeutic strategy for the prevention and treatment of human diseases. Taken together, this book targets a wide audience of basic and clinical scientists, teachers and students interested in gaining a better understanding in the field of cannabinoids.

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.

This respected text from the American Society of Addiction Medicine is valuable for all physicians and mental-health personnel who specialize in addiction medicine and who treat patients with addiction disorders. The chapters blend scientific principles underlying addiction with the practical essentials of clinical addiction medicine. Many of the contributors are affiliated with leading government agencies that study addiction and its science, such as the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse. The book will appeal to a wide and interdisciplinary range of professionals, especially those with interest or duties relating to addiction-related disorders, and in particular physicians seeking certification status via either the American Board of Addiction Medicine or the American Board of Psychiatry and Neurology. A companion Website will offer the fully searchable text.

Unique in its breadth of coverage ranging from historical accounts of drug use to clinical and preclinical behavioral studies, Psychopharmacology is appropriate for undergraduates studying the relationships between the behavioral effects of psychoactive drugs and their mechanisms of action. 1. Chapter-opening vignettes foster student engagement 2. Breakout boxes present novel, and, in some cases, controversial topics for special discussion. Box themes include: History of Psychopharmacology; Pharmacology in Action; Clinical Applications; Of Special Interest; and The Cutting Edge. 3. The book is extensively illustrated with full-color photographs and line art depicting important concepts and experimental data 4. Section Summaries highlight key concepts from the section of text just read 5. Chapter-ending Recommended Readings offer suggestions for further study And the enhanced eBook provides an interactive learning pathway through the content. Meyer, Psychopharmacology and it's accompanying enhanced ebook provide engaging features like self-study questions, and clinical case studies, cutting edge research, and applied pharmacology to keep students focused on the content, while providing the scientific depth, breadth, and rigor required for the course.

The use of cannabinoid-based medicines (CBM), and cannabis in particular, has risen steadily among cancer and palliative care patients over the last few years. This textbook aims to address the multiple challenges facing healthcare providers regarding the use of CBM in this vulnerable patient population. It provides insight into the latest preclinical and clinical data and offers a practical approach on the use of CBM in a rapidly evolving landscape. It answers questions regarding the prescribing process and elucidates controversies regarding cannabis’ disease-modifying effects. The first chapters will review basic concepts of the endocannabinoid system and pharmacology of CBM, while focusing more specifically on the unique characteristics of two main cannabinoids: THC and CBD. Indicating which benefits can be expected from using either or both of these compounds, the book then addresses issues of drug-drug interactions and other challenges involved in prescribing CBM to frail patients with polypharmacy and multiple comorbidities. Comparing available products, both approved and non-approved by the FDA, the book discusses regional challenges for accessing reliably tested and labelled products in the context of standardization efforts. After carefully determining objectives and addressing patient expectations, further chapters will examine the different clinical settings in which CBM may be useful in cancer care and explore symptom management, including cancer pain, anxiety, nausea, and insomnia among others. The possible benefits of cannabis psychoactivity will also be discussed, including harm reduction strategies for patients who wish to explore these effects. Cannabis and Cannabinoid-Based Medicines in Cancer Care: A Comprehensive Guide to Medical Management serves as a comprehensive text for oncologists, palliative care specialists, general practitioners, and nurse practitioners working with cancer patients or in palliative care settings.

This book focuses on the role of the endocannabinoid system in local and systemic inflammation, with individual chapters written by experts in the field of cannabinoid research and medicine. The topics explore the actions of the endocannabinoid system on the immune system, including neuroinflammation in autoimmune disorders such as multiple sclerosis, and in neurodegenerative disorders such as Huntington's and Alzheimer's, as well as local and systemic inflammatory conditions affecting organs including the eye (uveitis and corneal inflammation), the bladder (interstitial cystitis), pancreas (diabetes), cardiovascular system (stroke), joints (arthritis), and sepsis. The objective of this book is to provide knowledge transfer on the use of cannabinoids in inflammatory disease by critically examining preclinical and clinical research on the immunomodulatory actions of the endocannabinoid system, with specific emphasis on the actions of cannabinoids in diseases where inflammation is a prominent component. By drawing these results together, we seek to provide further understanding of the complexities of endocannabinoid system modulation of immune function and identify potential uses and limitations for cannabinoid-based therapeutics.